Epo is involved in angiogenesis in human glioma

Journal of Neuro-Oncology

Volumn 102, Issue 1, 2011, Pages 51-58

  Nico, Beatrice ^a   Annese, Tiziana ^a   Guidolin, Diego ^b   Finato, Nicoletta ^c   Crivellato, Enrico ^c   Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

Angiogenesis; Chorioallantoic membrane; Epo; EpoR; Human glioma

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER INHIBITION; CARCINOGENESIS; CHICK; CHORIOALLANTOIS; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOTOMY; EMBRYO; ENDOTHELIUM CELL; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; PARACRINE SIGNALING; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR CELL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BRAIN NEOPLASMS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; ERYTHROPOIETIN; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, ERYTHROPOIETIN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79952188040     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0294-6     Document Type: Article

References (48)

1. Kleinhues P, Cavenee W (2000) Astrocytic tumors. In: Pathology and genetics of tumors of the nervous system. World Health Organization Classification of Tumours. ISN Neuropath Press, Basel, pp 9-52
2. Machein MR, Plate KH (2000) VEGF in brain tumors. J Neurooncol 50:109-120 (Pubitemid 32166295)
3. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297-310
4. Bernsen HJJA, Rijken PFJW, Peters JPW, Bakker H, van der Kogel A (1998) Delayed vascular changes after antiangiogenic therapy with anti-vascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Neurosurgery 43:570-575 (Pubitemid 28400129)
5. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314
6. Chamberlain MC (2008) Antiangiogenesis: biology and utility in the treatment of gliomas. Expert Rev Neurother 8:1419-1423
7. Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG (2002) Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 9:24-36
8. Nir I, Kohn S, Doron Y, Israel O, Front D (1986) Quantitative analysis of tight junctions and the uptake of 99mTc in human gliomas. Cancer Invest 4:519-524 (Pubitemid 17058045)
9. Dinda AK, Sarkar C, Roy S, Kharbanda K, Mathur M, Khosla AK, Banerji AK (1993) A transmission and scanning electron microscopic study of tumoral and peritumoral microblood vessels in human gliomas. Neurooncology 16:149-158 (Pubitemid 23304723)
10. Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, Wolburg H (2000) Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 100:323-331 (Pubitemid 30456160)
11. Rascher G, Fischmann A, Kröger S, Duffner F, Grote EH, Wolburg H (2002) Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol 104:85-91 (Pubitemid 36075363)
12. Ribatti D (2008) Erythropoietin, the first century. Leuk Res 32:1169-1172
13. Ribatti D (2010) Erythropoietin and tumor angiogenesis. Stem Cells Dev 19:1-4
14. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635-4640
15. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643-651 (Pubitemid 30161216)
16. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-10531
17. Sirén AL, Radyushkin K, Boretius S, Kammer D, Riechers CC, Natt O, Sargin D, Watanabe T, Sperling S, Michaelis T, Price J, Meyer B, Frahm J, Ehrenreich H (2006) Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain 129:480-489 (Pubitemid 43164370)
18. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, Sirén AL, Paulus W, Nave KA, Gold R, Bartels C (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130:2577-2588 (Pubitemid 47511714)
19. Ehrenrecich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505 (Pubitemid 36337492)
20. Yin D, Kawabata H, Tcherniamtchouk O, HuynH T, Black KL, Koeffler HP (2007) Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin. Int J Oncol 31:1193-1198
21. Krieg M, Marti HH, Plate KH (1998) Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 92:3388-3393 (Pubitemid 28492349)
22. Said HM, Hagermann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K, Vordermark D (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1α in human glioma in vitro and in vivo. Radiother Oncol 83:398-405 (Pubitemid 46907985)
23. Mittelbronn M, Capper D, Bunz B, Dietz K, Goeppert B, Ajaaj R, Tabatabai G, Stubenvoll F, Schlaszus H, Merseburger AS, Becker R, Freudenstein D, Wick W, Weller M, Mayermann R, Simon P (2007) De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol 33:299-307 (Pubitemid 46701048)
24. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M (2004) Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35:1732-1737 (Pubitemid 38823656)
25. Ribatti D (2010) The chick embryo chorioallantoic membrane in the study of angiogenesis and metastasis. Springer, Berlin
26. Kelinhues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3:255-268 (Pubitemid 23276692)
27. Elias H, Hyde DM (eds) (1983) Stereological measurements of isotropic structures. In: A guide to practical stereology. Basel, Karger, pp 22-44
28. Guidolin D, Zunarelli E, Genedani S, Trentini GP, De Gaetani C, Fuxe K, Benagiano C, Agnati LF (2008) Opposite patterns of age-associated changes in neurons and glial cells of the thalamus of human brain. Neurobiol Aging 29:926-936 (Pubitemid 351618343)
29. Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD, Kalra VK, Malik P (2003) Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 102:1506-1514 (Pubitemid 36988063)
30. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26:132-149
31. Kayser K, Gabius HJ (1992) Analysis of expression of erythropoietin- binding sites in human lung carcinoma by the biotinylated ligand. Zentrabl Pathol 138:266-270
32. Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58:647-657 (Pubitemid 30620014)
33. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagao M, Sasaki R, Nakamura Y (2001) Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84:836-843 (Pubitemid 32275660)
34. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y (2002) Erythropoietin is involved in growth and angiogenesis in malignant tumors of female reproductive organs. Carcinogenesis 23:1797-1805 (Pubitemid 35355929)
35. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162:1789-1806 (Pubitemid 36613038)
36. Batra S, Perelman N, Luck LR, Shimada H, Malik P (2003) Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477-1487 (Pubitemid 37267831)
37. Hengartner MO, Horvitz HR (1994) C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian protooncogene bcl-2. Cell 76:665-676 (Pubitemid 24070651)
38. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A (2002) Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95:969-981 (Pubitemid 34925345)
39. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA (2002) Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82:911-918 (Pubitemid 34761666)
40. Dillard DG, Venkatraman G, Cohen C, Delgaudio J, Gal AA, Mattox DE (2001) Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol 121:149-152 (Pubitemid 32328556)
41. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021-1029 (Pubitemid 36833185)
42. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H (2008) Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10:932-939
43. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, Vujaskovic Z, Dewhirst MW, Arcasoy MO (2007) Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2:e549
44. Olujohungbe A, Handa S, Holmes J (1987) Do erythropoietin accelerate malignant transformation in multiple myeloma? Postgrad Med J 73:163-164
45. Bunworasate U, Arnouk H, Mindermal H, O'Loughlin KL, Sait SN, Barcos M, Stewart CC, Baer MR (2001) Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 98:3492-3494
46. Ribatti D (2002) A potential role of erythropoietin in angiogenesis associated with myelodysplastic syndromes. Leukemia 16:1890
47. Crivellato E, Nico B, Vacca A, Djonov V, Presta M, Ribatti D (2004) Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia 18:331-336 (Pubitemid 38240050)
48. Nico B, Crivellato E, Guidolin D, Annese T, Annese T, Longo V, Finato N, Vacca A, Ribatti D (2010) Intussusceptive microvascular growth in human glioma. Clin Exp Med 10:93-98